ADMA Biologics Inc is trading 7.6% up today at $8.74 following a bullish initiation from Raymond James.
- Raymond James issued an Outperform rating and a $21 price target, highlighting the company's successful shift into a profitable, high-growth plasma-derived biologics business.
- The analyst call has sparked significant investor optimism and trading interest, allowing the stock to decouple from broadly flat major indices.